These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34919827)

  • 21. Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins.
    Yuan M; Men Y; Kang J; Sun X; Zhao M; Bao Y; Yang X; Sun S; Ma Z; Wang J; Deng L; Wang W; Zhai Y; Liu W; Zhang T; Wang X; Bi N; Lv J; Liang J; Feng Q; Chen D; Xiao Z; Zhou Z; Wang L; Hui Z
    Thorac Cancer; 2021 Jan; 12(2):227-234. PubMed ID: 33247556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
    Altorki NK; McGraw TE; Borczuk AC; Saxena A; Port JL; Stiles BM; Lee BE; Sanfilippo NJ; Scheff RJ; Pua BB; Gruden JF; Christos PJ; Spinelli C; Gakuria J; Uppal M; Binder B; Elemento O; Ballman KV; Formenti SC
    Lancet Oncol; 2021 Jun; 22(6):824-835. PubMed ID: 34015311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
    Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
    Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved.
    Matsuguma H; Nakahara R; Ishikawa Y; Suzuki H; Inoue K; Katano S; Yokoi K
    Interact Cardiovasc Thorac Surg; 2008 Aug; 7(4):573-7. PubMed ID: 18413349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
    Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
    Zhou Q; Chen M; Jiang O; Pan Y; Hu D; Lin Q; Wu G; Cui J; Chang J; Cheng Y; Huang C; Liu A; Yang N; Gong Y; Zhu C; Ma Z; Fang J; Chen G; Zhao J; Shi A; Lin Y; Li G; Liu Y; Wang D; Wu R; Xu X; Shi J; Liu Z; Cui N; Wang J; Wang Q; Zhang R; Yang J; Wu YL
    Lancet Oncol; 2022 Feb; 23(2):209-219. PubMed ID: 35038429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy de-escalation using an
    Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
    Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes.
    Billiet C; De Ruysscher D; Peeters S; Decaluwé H; Vansteenkiste J; Dooms C; Deroose CM; De Leyn P; Hendrikx M; Bulens P; Le Péchoux C; Mebis J
    J Thorac Oncol; 2016 Sep; 11(9):1538-49. PubMed ID: 27374454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
    Hui Z; Men Y; Hu C; Kang J; Sun X; Bi N; Zhou Z; Liang J; Lv J; Feng Q; Xiao Z; Chen D; Wang Y; Li J; Wang J; Gao S; Wang L; He J
    JAMA Oncol; 2021 Aug; 7(8):1178-1185. PubMed ID: 34165501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
    Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
    Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
    Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
    Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
    Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
    Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
    Bellmunt J; Hussain M; Gschwend JE; Albers P; Oudard S; Castellano D; Daneshmand S; Nishiyama H; Majchrowicz M; Degaonkar V; Shi Y; Mariathasan S; Grivas P; Drakaki A; O'Donnell PH; Rosenberg JE; Geynisman DM; Petrylak DP; Hoffman-Censits J; Bedke J; Kalebasty AR; Zakharia Y; van der Heijden MS; Sternberg CN; Davarpanah NN; Powles T;
    Lancet Oncol; 2021 Apr; 22(4):525-537. PubMed ID: 33721560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer.
    Levy A; Mercier O; Le Péchoux C
    J Clin Oncol; 2022 Feb; 40(6):556-566. PubMed ID: 34985927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
    Albain KS; Swann RS; Rusch VW; Turrisi AT; Shepherd FA; Smith C; Chen Y; Livingston RB; Feins RH; Gandara DR; Fry WA; Darling G; Johnson DH; Green MR; Miller RC; Ley J; Sause WT; Cox JD
    Lancet; 2009 Aug; 374(9687):379-86. PubMed ID: 19632716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.